Annual Conference – Programme – Sarcopenia, Cachexia and Wasting Disorders

Choose your Timezone (Toggle Map):

Day 1

24 Jun 2022

Day 2

25 Jun 2022

Day 3

26 Jun 2022

10:00 - 11:00 CEST

OPENING SESSION

10:00 - 10:15 CEST

“Prometheus” basic science key note lecture – Targeting the ubiquitin proteasome system to fight muscle atrophy: update 2022

Volker Adams, Dresden, Germany

Adams, Volker

10:15 - 10:30 CEST

“Hippocrates” clinical science key note lecture

John Morley, Saint Louis, MO, USA

Morley, John E.

10:30 - 10:45 CEST

JCSM & SCWD lecture

Stephan von Haehling, Göttingen, Germany

von Haehling, Stephan

10:45 - 11:00 CEST

Discussion

All faculty

11:15 - 12:00 CEST

NOVEL ASPECTS OF ADIPOSE TISSUE FUNCTION IN WASTING (Clinical Session B)

11:15 - 11:23 CEST

Immune-sympathetic neuron communication guides adipose tissue browning in cancer-associated cachexia

Martina Schweiger, Graz, Austria

11:23 - 11:31 CEST

Angiocrine signals promote adipose tissue wasting in cancer cachexia

Andreas Fischer, Heidelberg, Germany

11:31 - 11:39 CEST

Brown adipose tissue activation is not related to hypermetabolism in emphysematous COPD patients

Annemie Schols, Maastricht, The Netherlands

Schols, Annemie

11:39 - 47 CEST

MRI-determined psoas muscle fat infiltration correlates with severity of weight loss during cancer cachexia

Dimitrios Karampinos, Munich, Germany

11:47 - 12:00 CEST

Discussion

All faculty

12:10 - 12:55 CEST

Lunchtime Sessions

13:00 - 13:45 CEST

Mechanisms of muscle loss due to cancer and chemotherapy and early interventions to help counteract negative effects (Clinical Session D)

13:00 - 13:08 CEST

Doxorubicin-induced skeletal muscle atrophy, underlying molecular pathways and potential protective effects of exercise: Evidence from pre- clinical and clinical data

Anouk E. Hiensch, Utrecht, The Netherlands

13:08 - 13:16 CEST

Exercise and Nutrition-based Rehabilitation programme (EneRgy) in people with cancer

TBD

13:16 - 13:24 CEST

Resistance training during chemotherapy for non-metastatic colon cancer: The FORCE study: Effects on body composition and physical function

Bette J. Caan, Oakland, CA, USA

Caan, Bette J.

13:24 - 13:32 CEST

Effects of exercise in patients after curative treatment for esophageal cancer: body composition and adequacy of energy and protein intake (the PERFECT study)

Anne M. May, Utrecht, The Netherlands

May, Ann M.

13:32 - 13:45 CEST

Discussion

All faculty

13:50 - 14:40 CEST

Poster and Rapid Fire Abstracts Sessions

14:45 - 15:30 CEST

New Basic Findings in Muscle Wasting
Basic Science Session E

14:45 - 14:53 CEST

Activation of Akt-mTORC1 signaling reverts cancer-dependent muscle wasting

Bert Blaauw, Padova, Italy

Blaauw, Bert

14:53 - 15:01 CEST

New insights into the role of GCN2-eIF2alpha signaling in the regulation of autophagy

Anne-Catherine Maurin, Clermont-Ferrand, France

15:01 - 15:09 CEST

Interventions for improving mitochondrial function to counteract cancer and chemotherapy-induced cachexia

Fabio Penna, Turin, Italy

Penna, Fabio

15:09 - 15:17 CEST

Fighting muscle loss: lessons from hibernation in brown bear

Etienne Lefai, Clermont-Ferrand, France

Lefai, Etienne

15:35 - 16:25 CEST

Poster and Rapid Fire Abstracts Sessions

16:30 - 17:15 CEST

Ammonia and the muscle- multiple diseases, one mechanism
Basic Science Session G

16:30 - 16:38 CEST

Mechanisms of ammonia induced sarcopenia – a common mediator in multiple diseases

Srinivasan Dasarathy, Cleveland, OH, USA

Dasarathy, Srinivasan

16:38 - 16:46 CEST

Multiomics based approaches to identify novel cellular and tissue responses

TBD

16:46 - 16:54 CEST

Hyperammonemia in disease – metabolic responses in the skeletal muscle

Steven W. M. Olde Damink, Maastricht, The Netherlands

Olde Damink, Steven W. M.

16:54 - 17:02 CEST

Amino acid perturbations in hyperammonemia

Milan Holecek, Hradec Kralove, Czech Republic

17:02 - 17:15 CEST

Discussion

All faculty

09:00 - 09:45 CEST

Liver alterations as drivers of cancer cachexia
Clinical Session H

09:00 - 09;15 CEST

Hepatic and intestinal disturbances as targets to counteract cancer cachexia

Laure Bindels, Leuven, Belgium

09:15 - 09:30 CEST

A cachexia score based on liver alterations predicts prognosis of gastrointestinal cancer patients

Achim Krüger, Munich, Germany

09:30 - 09:45 CEST

Discussion

All faculty

10:00 - 10:45 CEST

Hot topics in basic research: role of muscle stem and progenitor cells during aging, disease and regeneration
Basic Science Session K

10:00 - 10:08 CEST

Muscle stem cells in age and disease

Julia von Maltzahn, Leibniz, Germany

10:08 - 10:16 CEST

Neurofibromatosis type 1 associated myopathy is due to metabolic reprogramming of muscle stem cells in a mouse model

Sigmar Stricker, Berlin, Germany

10:16 - 10:24 CEST

Fibro-adipogenic progenitors coordinate muscle regeneration

Georgios Kotsaris, Berlin, Germany

10:24 - 10:32 CEST

Activating stem cells to drive muscle regeneration in cancer

Jason D. Doles, Rochester, MN, USA

Doles, Jason D.

10:32 - 10:45 CEST

Discussion

All faculty

10:50 - 11:40 CEST

Poster and Rapid Fire Abstracts Sessions

11:45 - 12:30 CEST

State of the art nutrition for outcome driven cancer treatments
Clinical Session N

11:45 - 11:53 CEST

Integrated evaluation of body composition in the oncology setting: paradigm change

David da Silva Dias, Faro, Portugal

11:53 - 12:01 CEST

Nutrition Options in 2022: What is on the market?

Paula Ravasco, Lisbon, Portugal

12:01 - 12:09 CEST

Nutrition in ambulatory cytotoxic treatment: new data on the role of the clinical pharmacist

Leila Costa, Portugal

12:09 - 12:17 CEST

Head and neck cancer and cachexia – a high risk cancer and higher risk treatments

TBD

12:17 - 12:30 CEST

Discussion

All faculty

12:40 - 13:40 CEST

Lunchtime sessions

13:50 - 14:35 CEST

Novel cachexia mediators – proteins and beyond
Basic Science Session O

13:50 - 13:58 CEST

Early neutrophilia marked by aerobic glycolysis sustains host metabolism and delays cancer cachexia

Tobias Janowitz, Cold Spring Harbor, NY, USA

Janowitz, Tobias

13:58 - 14:06 CEST

Tumor-derived cachexia mediators and biomarkers

Mauricio Berriel Diaz, Neuherberg, Germany

Berriel Diaz, Mauricio

14:06 - 14:14 CEST

Tumor-derived extracellular vesicles

Paola Costelli, Turin, Italy

Costelli, Paola

14:08 - 14:22 CEST

Oncometabolites and cachexia

TBD

14:22 - 14:35 CEST

Discussion

All faculty

14:40 - 15:30 CEST

Poster session

15:35 - 16:20 CEST

Mechanisms of energy and anabolic crisis in cancer cachexia – new therapeutic targets?
Basic Science Session Q

15:35 - 15:43 CEST

MyomiRNA, systemic and local inflammation and muscle wasting

Maurizio Muscaritoli, Rome, Italy

Muscaritoli, Maurizio

15:43 - 15:51 CEST

FFA1R agonists in cancer cachexia

TBD

15:51 - 15:59 CEST

The transcriptional repressor FoxP1 in cancer-induced skeletal muscle wasting and weakness

Sarah M. Judge, Gainesville, FL, USA

15:59 - 16:07 CEST

Cancer-derived extracellular vesicles as mediators of lipolysis and adipose tissue browning

TBD

16:07 - 16:20 CEST

Discussion

All faculty

16:35 - 17:20 CEST

Cachexia-associated microenvironment alterations
Basic Science Session S

16:35 - 16:45 CEST

Endothelial dysfunction in cachexia

Young-Mee Kim, Coral Gables, FL, USA

16:45 - 16:55 CEST

Immunity in cachexia

TBD

16:55 - 17:05 CEST

NMJ defects and stem cell defects in wasting muscle

Joe Chakkalakal, Durham, NC, USA

17:05 -17:20 CEST

Discussion

All faculty

17:35 - 18:20 CEST

Host-specific and tumor-specific molecular mechanisms of biological variability in cancer cachexia
Basic Science Session U

17:35 - 17:43 CEST

Host factors: sexual dimorphism in murine models of cancer cachexia

Nicholas P. Greene, Fayetteville, AR, USA

Greene, Nicholas P.

17:43 - 17:51 CEST

Host factors: aging and host genotype in cancer cachexia

Maria Rohm, Neuherberg, Germany

Rohm, Maria

17:51 - 17:59 CEST

Tumor factors: tumor molecular and cellular heterogeneity mediates cancer cachexia phenotype

Teresa A. Zimmers, Indianapolis, IN, USA

Zimmers, Teresa A.

17:59 - 18:07 CEST

In vivo screening reveals lung cancer tumor-specific mediators of cancer cachexia in mice

Rodney Infante, Dallas, TX, USA

Infante, Rodney

18:07 - 18:20 CEST

Discussion

All faculty

09:00 - 09:50 CEST

Covid-19 and cachexia: common players and perspectives
Session W

09:00 - 09:10 CEST

The role of adipose tissue in Covid-19 cytokine storm: learning from cachexia

Marilia Seelaender, São Paulo, Brazil

Seelaender, Marilia

09:10 - 09:20 CEST

Nutrition: a matter of life or death

Alessandro Laviano, Rome, Italy

Laviano, Alessandro

09:20 - 09:30 CEST

Body composition and muscle quality in Covid-19 patients

Carla Prado, Edmonton, Alberta, Canada

Prado, Carla

09:30 - 09:40 CEST

Frailty and rehabilitation in Covid-19 patients

Francesco Landi, Rome, Italy

Landi, Francesco

09:40 - 09:50 CEST

Discussion

All faculty

10:00 - 10:50 CEST

Multi-modal interventions for cachexia
Session X

10:00 - 10:15 CEST

Evolution and outcomes from a multi-disciplinary cachexia clinic

Peter Martin, Melbourne, Australia

10:15 - 10:30 CEST

The importance of exercise and nutrition in an integrated response to cachexia management

Adrian Slee, London, United Kingdom

Slee, Adrian

10:30 - 10:50 CEST

Discussion

All faculty

11:00 - 11:50 CEST

Mechanisms of cancer cachexia – transition from basic research to clinical investigation
Session Y

11:00 - 11:10 CEST

MEF2c-dependent downregulation of myocilin mediates cancer-induced muscle wasting and associates with cachexia in patients with cancer

Andrew R. Judge, Gainesville, FL, USA

Judge, Andrew

11:10 - 11:20 CEST

Activation of p38β MAPK in skeletal muscle correlates with weight loss in cancer patients

Yi-Ping Li, Houston, TX, USA

Li, Yi-Ping

11:20 - 11:30 CEST

Association between growth differentiation factor-15 (GDF-15) serum levels, anorexia and low muscle mass among cancer patients

Alessio Molfino, Rome, Italy

11:30 - 11:40 CEST

Adipose depot gene expression and intelectin-1 in the metabolic response to cancer and cachexia

Richard J. E. Skipworth, Edinburgh, United Kingdom

Skipworth, Richard J. E.

11:40 - 11:50 CEST

Discussion

All faculty

12:00 - 12:45 CEST

Lunchtime session

14:00 - 14:50 CEST

Targeting cachexia treatment: GDF15 and beyond
Session Z

14:01 14-08 CEST

GDF15 neutralization as a transformative therapeutic approach

Bei Zhang, Cambridge, MA, USA

Zhang, Bei B.

14:08 - 14:16 CEST

GFRAL antibody in cancer cachexia

TBD

14:16 - 14:24 CEST

GDF-15 in the treatment of obesity

TBD

14:24 - 14:32 CEST

Activation of the hypothalamic–pituitary–adrenal axis by exogenous and endogenous GDF15

Danna Breen, Cambridge, MA, USA

14:32 - 14:40 CEST

MC4R antagonism for appetite and body weight regulation – from human genetics to aged rat model

Zhidan Wu, Cambridge, MA, USA

Wu, Zhidan

14:40 - 14:50 CEST

Discussion

* CEST, Central European Summer Time (UTC +2)

OPENING SESSION

“Prometheus” basic science key note lecture – Targeting the ubiquitin proteasome system to fight muscle atrophy: update 2022

“Hippocrates” clinical science key note lecture

JCSM & SCWD lecture

Discussion

NOVEL ASPECTS OF ADIPOSE TISSUE FUNCTION IN WASTING (Clinical Session B)

Immune-sympathetic neuron communication guides adipose tissue browning in cancer-associated cachexia

Angiocrine signals promote adipose tissue wasting in cancer cachexia

Brown adipose tissue activation is not related to hypermetabolism in emphysematous COPD patients

MRI-determined psoas muscle fat infiltration correlates with severity of weight loss during cancer cachexia

Discussion

Lunchtime Sessions

Mechanisms of muscle loss due to cancer and chemotherapy and early interventions to help counteract negative effects (Clinical Session D)

Doxorubicin-induced skeletal muscle atrophy, underlying molecular pathways and potential protective effects of exercise: Evidence from pre- clinical and clinical data

Exercise and Nutrition-based Rehabilitation programme (EneRgy) in people with cancer

Resistance training during chemotherapy for non-metastatic colon cancer: The FORCE study: Effects on body composition and physical function

Effects of exercise in patients after curative treatment for esophageal cancer: body composition and adequacy of energy and protein intake (the PERFECT study)

Discussion

Poster and Rapid Fire Abstracts Sessions

New Basic Findings in Muscle Wasting Basic Science Session E

Activation of Akt-mTORC1 signaling reverts cancer-dependent muscle wasting

New insights into the role of GCN2-eIF2alpha signaling in the regulation of autophagy

Interventions for improving mitochondrial function to counteract cancer and chemotherapy-induced cachexia

Fighting muscle loss: lessons from hibernation in brown bear

Poster and Rapid Fire Abstracts Sessions

Ammonia and the muscle- multiple diseases, one mechanismBasic Science Session G

Mechanisms of ammonia induced sarcopenia – a common mediator in multiple diseases

Multiomics based approaches to identify novel cellular and tissue responses

Hyperammonemia in disease – metabolic responses in the skeletal muscle

Amino acid perturbations in hyperammonemia

Discussion

Liver alterations as drivers of cancer cachexiaClinical Session H

Hepatic and intestinal disturbances as targets to counteract cancer cachexia

A cachexia score based on liver alterations predicts prognosis of gastrointestinal cancer patients

Discussion

Hot topics in basic research: role of muscle stem and progenitor cells during aging, disease and regenerationBasic Science Session K

Muscle stem cells in age and disease

Neurofibromatosis type 1 associated myopathy is due to metabolic reprogramming of muscle stem cells in a mouse model

Fibro-adipogenic progenitors coordinate muscle regeneration

Activating stem cells to drive muscle regeneration in cancer

Discussion

Poster and Rapid Fire Abstracts Sessions

State of the art nutrition for outcome driven cancer treatmentsClinical Session N

Integrated evaluation of body composition in the oncology setting: paradigm change

Nutrition Options in 2022: What is on the market?

Nutrition in ambulatory cytotoxic treatment: new data on the role of the clinical pharmacist

Head and neck cancer and cachexia – a high risk cancer and higher risk treatments

Discussion

Lunchtime sessions

Novel cachexia mediators – proteins and beyondBasic Science Session O

Early neutrophilia marked by aerobic glycolysis sustains host metabolism and delays cancer cachexia

Tumor-derived cachexia mediators and biomarkers

Tumor-derived extracellular vesicles

Oncometabolites and cachexia

Discussion

Poster session

Mechanisms of energy and anabolic crisis in cancer cachexia – new therapeutic targets?Basic Science Session Q

MyomiRNA, systemic and local inflammation and muscle wasting

FFA1R agonists in cancer cachexia

The transcriptional repressor FoxP1 in cancer-induced skeletal muscle wasting and weakness

Cancer-derived extracellular vesicles as mediators of lipolysis and adipose tissue browning

Discussion

Cachexia-associated microenvironment alterations Basic Science Session S

Endothelial dysfunction in cachexia

Immunity in cachexia

NMJ defects and stem cell defects in wasting muscle

Discussion

Host-specific and tumor-specific molecular mechanisms of biological variability in cancer cachexiaBasic Science Session U

Host factors: sexual dimorphism in murine models of cancer cachexia

Host factors: aging and host genotype in cancer cachexia

Tumor factors: tumor molecular and cellular heterogeneity mediates cancer cachexia phenotype

In vivo screening reveals lung cancer tumor-specific mediators of cancer cachexia in mice

Discussion

Covid-19 and cachexia: common players and perspectivesSession W

The role of adipose tissue in Covid-19 cytokine storm: learning from cachexia

Nutrition: a matter of life or death

Body composition and muscle quality in Covid-19 patients

Frailty and rehabilitation in Covid-19 patients

New Basic Findings in Muscle Wasting
Basic Science Session E

Ammonia and the muscle- multiple diseases, one mechanism
Basic Science Session G

Liver alterations as drivers of cancer cachexia
Clinical Session H

Hot topics in basic research: role of muscle stem and progenitor cells during aging, disease and regeneration
Basic Science Session K

State of the art nutrition for outcome driven cancer treatments
Clinical Session N

Novel cachexia mediators – proteins and beyond
Basic Science Session O

Mechanisms of energy and anabolic crisis in cancer cachexia – new therapeutic targets?
Basic Science Session Q

Cachexia-associated microenvironment alterations
Basic Science Session S

Host-specific and tumor-specific molecular mechanisms of biological variability in cancer cachexia
Basic Science Session U

Covid-19 and cachexia: common players and perspectives
Session W